TY - JOUR
T1 - Overview of Binge Eating Disorder
AU - Davis, Heather A.
AU - Graham, Andrea K.
AU - Wildes, Jennifer E.
N1 - Funding Information:
This work was supported by grants from the National Institutes of Health (T32 MH082761 and K01 DK116925).
Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Purpose of Review: Binge eating disorder (BED) is characterized by recurrent binge eating episodes (i.e., eating an objectively large amount of food accompanied by a sense of loss of control while eating) in the absence of regular compensatory behavior. BED follows a chronic course marked by significant dysfunction and impairment. This review focuses on advances in the understanding of BED, including its diagnosis, correlates, risk factors, and treatment, with particular attention to the past 5 to 8 years. Recent Findings: BED remains the most common eating disorder in the USA and globally. BED occurs across the lifespan and among diverse gender, racial, and ethnic groups. Risk for and maintenance of BED results from multiple psychological, biological, and sociocultural factors. First-line treatment for reducing binge eating is cognitive behavioral therapy, with efficacy for interpersonal psychotherapy as well. Lisdexamfetamine is an FDA-approved medication for moderate to severe cases of BED. Summary: Even with advances in its diagnosis and treatment, better assessment and understanding of BED in diverse gender, racial, and ethnic populations is needed. Studies of shared risk factors underlying BED and comorbid disorders may lead to a greater understanding of mechanisms for intervention. Future research should prioritize evaluating the implementation of established treatments among populations in need, as well as establishing new interventions that can be scaled for delivery in real-world settings. Given overlap between BED and overweight/obesity, a continued focus on developing treatments that effectively address binge eating and weight management is warranted.
AB - Purpose of Review: Binge eating disorder (BED) is characterized by recurrent binge eating episodes (i.e., eating an objectively large amount of food accompanied by a sense of loss of control while eating) in the absence of regular compensatory behavior. BED follows a chronic course marked by significant dysfunction and impairment. This review focuses on advances in the understanding of BED, including its diagnosis, correlates, risk factors, and treatment, with particular attention to the past 5 to 8 years. Recent Findings: BED remains the most common eating disorder in the USA and globally. BED occurs across the lifespan and among diverse gender, racial, and ethnic groups. Risk for and maintenance of BED results from multiple psychological, biological, and sociocultural factors. First-line treatment for reducing binge eating is cognitive behavioral therapy, with efficacy for interpersonal psychotherapy as well. Lisdexamfetamine is an FDA-approved medication for moderate to severe cases of BED. Summary: Even with advances in its diagnosis and treatment, better assessment and understanding of BED in diverse gender, racial, and ethnic populations is needed. Studies of shared risk factors underlying BED and comorbid disorders may lead to a greater understanding of mechanisms for intervention. Future research should prioritize evaluating the implementation of established treatments among populations in need, as well as establishing new interventions that can be scaled for delivery in real-world settings. Given overlap between BED and overweight/obesity, a continued focus on developing treatments that effectively address binge eating and weight management is warranted.
KW - Binge eating disorder
KW - Diagnosis
KW - Epidemiology
KW - Mechanisms
KW - Risk factors
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85094951270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094951270&partnerID=8YFLogxK
U2 - 10.1007/s12170-020-00664-2
DO - 10.1007/s12170-020-00664-2
M3 - Review article
AN - SCOPUS:85094951270
SN - 1932-9520
VL - 14
JO - Current Cardiovascular Risk Reports
JF - Current Cardiovascular Risk Reports
IS - 12
M1 - 26
ER -